Impact Factor 2017: 1.634 (@Clarivate Analytics)
5-Year Impact Factor: 1.677 (@Clarivate Analytics)
  • Users Online: 632
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2018  |  Volume : 11  |  Issue : 4  |  Page : 297-304

EPOR mRNA level: A valuable prognostic indicator for patients with ER+ breast cancer


1 Department of Medical Oncology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, P.R. China
2 Department of Medical Oncology, Anhui Provincial Hospital, Anhui Medical University; Department of Medical Oncology, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, P.R. China

Correspondence Address:
Yue-Yin Pan
Department of Medical Oncology, The First Affiliated Hospital of University of Science and Technology of China, No.17 Lujiang Road, Luyang District, Hefei 230001
P.R. China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.231471

Get Permissions

Objective: To explore the expression level and prognostic significance of erythropoietin receptor (EPOR) in patients with breast cancer (BRCA) based on estrogen receptor (ER) status and different molecular subtypes. Methods: The Cancer Genome Atlas (TCGA) and GTEx data were collected in GEPIA initially to identify the dysregulated genes. Further, bc- GenExMiner 4.1 online bioinformatics tool was used to evaluate EPOR mRNA differential expression level according to different classification of clinicopathologic parameters in patients with breast cancer. Additionally, the prognostic value between EPOR mRNA expression and free survival of metastatic relapse (MR) or any event (AE, namely any relapse or death) in patients with breast cancer was done. Results: EPOR mRNA was significantly downregulated in BRCA (1 085 cases) compared to normal tissues (291 cases) (P<0.05). Univariate Cox analysis revealed that high EPOR mRNA expression was remarkably correlated to a decreased risk of MR (HR: 0.79, P<0.000 1) and AE (HR: 0.87, P =0.000 7) especially in breast cancer patients with ER+. Besides, high EPOR mRNA level also associated with a favorable MR- free survival (HR: 0.81, P =0.007 2) and AE-free survival (HR: 0.88, P =0.029 9) in ER+ breast cancer patients. However, no similar above phenomenon was detected in ER- patients. Moreover, the subsequent prognostic adjusted analyses and univariate Cox analysis of AE based on SSP or SCM molecular subtypes validated the above results. Conclusion: EPOR mRNA level is a valuable prognostic indicator for patients with ER+ breast cancer.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed565    
    Printed25    
    Emailed0    
    PDF Downloaded83    
    Comments [Add]    

Recommend this journal